Steve Warner

Company: Sumitomo Pharma Oncology

Job title: Senior Vice President & Head of US Research

Seminars:

Exploiting Vulnerabilities in Cancer with Next Generation DDR Inhibitors Targeting Cyclin K or PARG 2:45 pm

Cyclin K degrading molecular glues potentially target CDK12/13-driven expression of DDR genes PARG inhibitors may target homologous recombination deficiencies in cancer in a complementary and differentiated way than PARP inhibitors Targeting Cyclin K or PARG may provide opportunities to inhibit DDR pathways that leverage contextual vulnerabilities in cancer, including CDK12-amplified cancers and PARPi-resistant HRD-positive cancersRead more

day: Day One